Nicholas Hornstein
@GIMedOnc
GI Med Oncologist @NorthwellHealth via Fellow@MDAndersonNews + IM@UCLAHealth | CUMC ‘18 | Interests: Comp Biology, Clinical Trials, Colon Cancer, CUP
OncoAlert out again this week helping me stay updated across a variety of tumor types! Lung once leading the pack (still jealous they get all the drugs first); some interesting studies coming out for prostate and breast as well. oncoalert.m-pages.com/nhMpwe/oncoale… @OncoAlert
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 18-24, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: 🫁🧬 ✅News From Industry: FLAURA2 Update #NSCLC 🫁 ✅Exercise in met #ProstateCancer ✅Surgery🆚RT☢️in Prostate…
It was my thirteenth straight day of work. A Saturday on call—routine, in the way hospital days often are. I stepped outside for a quick lunch, finally out of scrubs and in a T-shirt and jeans, hoping to feel just a little removed from it all. I sat on a bench just beyond the…
The lab delivers!
Excited to share that @sidmahajan11 (@MacNealHosp) @SuriyaBaskarMD @official_tbhc) & Matt Gao (@IowaMed) had abstracts accepted for poster presentation at @ASCO Qlty Care Symp #ASCOQLTY25 @TimothyJBrownMD @UGrewalMD @GIMedOnc @Deebacca @sawyer_bawek @BRoseMDMPH Phenomenal work 👏
Are you, like me, starting to get overwhelmed with the wealth of options in upper GI? HER2 PDL1 MSI-H CLDN18.2 (Now FGFR2) Well, @UGrewalMD and @TimothyJBrownMD have a great review article piecing it all together. Next goal... Get one person on tumor board to stop recommending…
Checkout this piece where @TimothyJBrownMD and I try to take on the challenging task of describing zolbetuximab’s place in the advanced GEC treatment paradigm. @TheGutOncLab @GIMedOnc @Deebacca P.S. we are already thinking about how we’re going to update this algorithm to…
As we’ve launched a new HAI program in Manhattan at Northwell, questions around optimal dosing strategies are front and center. This new @cityofhope study asks: can we de-escalate initial FUDR dosing and still preserve outcomes in adjuvant HAI? Retrospective and single-center —…
Another new paper out! Grateful to have been a part of the effort. We (Andrew Pellatt and Arvind Dasari) asked: Can TAS-102 eliminate ctDNA-defined MRD in CRC after adjuvant chemo? 💊 Single-arm phase II study of CRC pts with MRD by ctDNA after curative-intent therapy (Stage…
💥New paper out! We reanalyzed raw sequencing data from 18,558 standard-of-care Guardant360 ctDNA assays in advanced #colorectalcancer using a partner-agnostic fusion caller. 🧬 Fusions in 1.3% of patients 🧪 93% were subclonal — enriched after EGFR therapy 🔗 Clonal fusions…
So much good science! Gut Onc Lab should be well represented at GI-ASCO. Really excited for some of the things we’re working on as they’re progressing from concept, to data and now publication.
We are growing!!! Love our biweekly lab meetings and all the cool ideas/collaborations. We are also trying to match @Deebacca’s background game; guess we will get there one day. Watch this space for more 🚀 🔥 @TimothyJBrownMD @GIMedOnc @UGrewalMD @BRoseMDMPH @sawyer_bawek
Lots of great discussion in this weeks RoundUp! I’ve never been the biggest fan of PARPi in bio-marked unselected patients, but I guess that is where the field is heading. ACCORD with some interesting results… Is it the Carmelizumab (PD1) or the RT driving the show? Not sure,…
The OncoAlert WEEKLY RoundUp 🚨 Covering the TOP of the week July 11-17, 2025 👉REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅TALAPRO2 in #ProstateCancer ✅Geriatric Assessment 👴 ✅Molecular Landscape of Non Clear Cell Renal Carcinoma…
Headlines rarely tell the whole story. When pembrolizumab was first approved in advanced gastric and GEJ cancer, the approvals seemed broad: combinations with chemo, HER2-targeted therapy, first-line, later-line — PD-L1 status didn’t seem to matter. But as more data emerged,…
The OncoAlert🚨Weekly Round Up Covering the TOP of the week July 4-10, 2025 REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale… Discussing: ✅News From Industry: durvalumab in #BladderCancer ✅PRIM-B in metastatic #BreastCancer ✅Breastfeeding after breast…
This is hands down one of the best discussions on the changing paradigm in upper GI cancers that I have watched in recent times. Just fantastic! It’s well worth your time. Do watch. @TheGutOncLab @GIMedOnc @Deebacca @OncBrothers
GI Onc Expert Interview! Here I talk esophagogastric cancers w all-star GI med oncs @KlempnerSam & @TimothyJBrownMD We discuss: 1) MATTERHORN: D-FLOT for all? Extrapolate to esophagus? Need for adj durva? 2) Organ preservation: SANO trial, & overall paradigm Full video link👇
🚀 Excited to share our new review in @Nature_NPJ Precision Oncology: “Mucin-1: A Promising Pan-Cancer Therapeutic Target” nature.com/articles/s4169… We discuss: ✅ How aberrant MUC1 expression and glycosylation drive oncogenesis in solid and hematologic cancers ✅ The pipeline of…
Top 10 #GICancer Oncologists for June 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | @ArndtVogel | @Erman_Akkus |…
ATOMIC and CHALLENGE were two practice changing studies from #ASCO25 How we incorporate them into daily practice is critical. @OncoAlert @TheGutOncLab
Nicholas James Hornstein, MD, discussed the ATOMIC and CHALLENGE Trials in a post-@ASCO interview. #gicsm | @GIMedOnc cancernetwork.com/view/exercise-…
🚨I'm hiring at Northwell!🚨 If you—or someone you know—has a passion for using data to drive progress in cancer care, this is a great opportunity. We’re looking for a Data Scientist with expertise in NLP and machine learning to join our team at the Northwell Health Cancer…
🚨 Practice-Changing Data in HER2+ Gastric Cancer (May 31 Publication, but now with a video!) In the phase 3 DESTINY-Gastric04 trial, trastuzumab deruxtecan (T-DXd) significantly improved overall survival vs ramucirumab + paclitaxel in the 2nd-line setting for patients with…
The @OncoAlert @VJOncology JOURNAL CLUB This week we have the pleasure to bring you our OncoAlert Colleague @KoheiShitara 🇯🇵Discussing his paper: Trastuzumab Durextecan or Ramucirumab plus paclitaxel in gastric cancer out on NEJM nejm.org/doi/10.1056/NE… #OncoAlertAF…
Cheers to a very productive Gut Onc Lab meeting. Cool ideas and great progress. Excited for what’s to come. #GIOnc #DreamTeam @GIMedOnc @TimothyJBrownMD @Deebacca @UGrewalMD @sidmahajan11 @sawyer_bawek 💯😎